Evidence map›Paper›PMID 40658306›Full record

ArticleInternational journal of clinical oncology2025

Risk stratification for recurrence after nephrectomy in high-risk renal cell carcinoma patients.

Taisuke Tobe, Jun Teishima, Hideto Ueki, Yusuke Shiraishi, Naoto Wakita, Yasuyoshi Okamura, Kotaro Suzuki, Yukari Bando, Takuto Hara, Tomoaki Terakawa and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Taisuke TobeDivision of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki, Chuo-Ku, Kobe, Hyogo, 650-0017, Japan.
Jun TeishimaDivision of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki, Chuo-Ku, Kobe, Hyogo, 650-0017, Japan. teishimaj@yahoo.co.jp.ORCID http://orcid.org/0000-0001-8429-1607
Hideto UekiDivision of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki, Chuo-Ku, Kobe, Hyogo, 650-0017, Japan.
Yusuke ShiraishiDivision of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki, Chuo-Ku, Kobe, Hyogo, 650-0017, Japan.
Naoto WakitaDivision of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki, Chuo-Ku, Kobe, Hyogo, 650-0017, Japan.
Yasuyoshi OkamuraDivision of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki, Chuo-Ku, Kobe, Hyogo, 650-0017, Japan.
Kotaro SuzukiDivision of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki, Chuo-Ku, Kobe, Hyogo, 650-0017, Japan.
Yukari BandoDivision of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki, Chuo-Ku, Kobe, Hyogo, 650-0017, Japan.
Takuto HaraDivision of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki, Chuo-Ku, Kobe, Hyogo, 650-0017, Japan.
Tomoaki TerakawaDivision of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki, Chuo-Ku, Kobe, Hyogo, 650-0017, Japan.
Koji ChibaDivision of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki, Chuo-Ku, Kobe, Hyogo, 650-0017, Japan.
Akihisa YaoDivision of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki, Chuo-Ku, Kobe, Hyogo, 650-0017, Japan.
Hideaki MiyakeDivision of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki, Chuo-Ku, Kobe, Hyogo, 650-0017, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo identify prognostic factors that guide adjuvant therapy decisions, we investigated factors predicting recurrence in patients with high-risk clear cell renal cell carcinoma (RCC) after nephrectomy.

methodsWe retrospectively reviewed patients with non-metastatic, high-risk clear cell RCC who underwent radical or partial nephrectomy at our institution and affiliated centers between January 2016 and March 2024. Multivariate analysis using the Cox proportional hazards model was performed to identify clinicopathological factors associated with recurrence. On the basis of these factors, we developed a risk stratification model.

resultsA total of 338 patients were included. The 5-year recurrence-free survival (RFS) rate was 54.3%. Multivariate analysis identified a body mass index of ≤ 22 kg/m

conclusionWe identified independent predictors of recurrence in patients with nephrectomy-treated clear cell RCC. Patients stratified according to a risk score based on these factors had different recurrence rates, suggesting that this score could assist in guiding adjuvant therapy decisions.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsNeoplasm Recurrence, LocalNephrectomyAdultAgedFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesRisk AssessmentRisk FactorsAdjuvant therapyNephrectomyPembrolizumabRenal cell carcinomaRisk stratification

Identifiers

PMID40658306

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.